Explore
Trendline
Angelini Pharma Expands into U.S. Market with $4.1 Billion Acquisition of Catalyst Pharma
Angelini Pharma Expands into U.S. Market with $4.1 Billion Acquisition of Catalyst Pharma
Read More
Trendline
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Expand in U.S. Rare Disease Market
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Expand in U.S. Rare Disease Market
Read More
Trendline
Disney's Streaming and Theme Parks Drive Strong Second Quarter Performance
Disney's Streaming and Theme Parks Drive Strong Second Quarter Performance
Read More
Trendline
Innoviva Reports Strong Q1 2026 Financial Results with Significant Growth in U.S. Sales
Innoviva Reports Strong Q1 2026 Financial Results with Significant Growth in U.S. Sales
Read More
Trendline
Sigma Foods Acquires Roger Wood Foods, Expanding U.S. Presence in Smoked Meats
Sigma Foods Acquires Roger Wood Foods, Expanding U.S. Presence in Smoked Meats
Read More
Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Read More
Trendline
GameStop Proposes $55.5 Billion Acquisition of eBay to Compete with Amazon
GameStop Proposes $55.5 Billion Acquisition of eBay to Compete with Amazon
Read More
Trendline
PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities Amid Global Expansion
PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities Amid Global Expansion
Read More
Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Read More
Trendline
Steute Technologies Expands U.S. Presence with Three Strategic Acquisitions
Steute Technologies Expands U.S. Presence with Three Strategic Acquisitions
Read More
Trendline
GameStop's $56 Billion Bid for eBay Aims to Challenge Amazon
GameStop's $56 Billion Bid for eBay Aims to Challenge Amazon
Read More
Trendline
UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal
UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal
Read More